Advertisement

Search Results

Advertisement



Your search for The A matches 32997 pages

Showing 22251 - 22300


solid tumors
bladder cancer

High-Intensity Local Treatment May Improve Survival in Patients With Metastatic Urothelial Carcinoma of the Bladder

In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Seisen et al found that high-intensity local treatment was associated with an overall survival benefit in patients with metastatic urothelial carcinoma of the bladder. Study Details The study included data from...

solid tumors

Vemurafenib Active in BRAF V600E–Positive Papillary Thyroid Cancer Refractory to Radioactive Iodine

In a phase II study reported in The Lancet Oncology, Brose et al found that vemurafenib (Zelboraf) had antitumor activity in patients with BRAF V600E–positive recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine. Study Details In the study, 26 patients without...

lymphoma

Is Post-Transplantation Cyclophosphamide Disruptive Technology?

There was a time when transplantation across human leukocyte antigen (HLA) barriers was fraught with so much difficulty that many thought it was impossible and we should stop trying. However, most patients do not have an HLA-matched sibling donor, and death was therefore certain if they had a...

lymphoma

Reduced-Intensity Related-Donor Haploidentical vs HLA-Matched Sibling-Donor Hematopoietic Cell Transplantation in Lymphoma

In an analysis of the observational database of the Center for International Blood and Marrow Transplant Research reported in the Journal of Clinical Oncology, Nilanjan Ghosh, MD, PhD, of Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina, and colleagues found that...

issues in oncology

Study Finds Low Engagement in Internet-Based Research in Underrepresented Population

A large study by Hartz et al examining whether Internet-based research approaches effectively engage participants from diverse racial and socioeconomic backgrounds has found engagement in this type of research to be low among participants without a high school education, those living below the...

issues in oncology

Effects of the Global Economic Crisis on Cancer Care

The global economic crisis beginning in 2008 was associated with substantial public health effects, especially with respect to mental health.1–3 Nevertheless, there is also evidence of a paradoxical association between recessions and reduced all-cause mortality, in part because of reductions in...

issues in oncology

Economic Crisis Associated With Increased Cancer Mortality

The global economic crisis has been associated with increased unemployment and reduced public-sector expenditure on health care. In a study reported in The Lancet, Mahiben Maruthappu, MA, of Imperial College London, and colleagues found that the global economic crisis beginning in 2008 was...

10 New ASTRO Fellows Named in 10th Anniversary of FASTRO Designation

Ten distinguished members of the American Society for Radiation Oncology (ASTRO) have been named ASTRO Fellows, in the 10th anniversary year that the designation has been awarded. The 2016 class of Fellows will be recognized at an awards ceremony during ­ASTRO’s 58th Annual Meeting, to be held...

Spotlight on Women Who Conquer Cancer

Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...

Making a Difference in Cancer Care With You: Daniel Hayes’ Presidential Theme

“Are you a member of ASCO?” I distinctly remember being asked that question in 1984, during my second year as a fellow at what was then the Sidney Farber (now Dana-Farber) Cancer Institute. My first reaction: “What’s an ASCO?” Turned out it was a) the Society that many of my mentors had or would...

Survivorship Resources for Providers and Patients

ASCO offers a product that combines provider and patient information about cancer survivorship. Providing High Quality Survivorship Care in Practice: An ASCO Guide aims to assist oncologists and other clinicians with implementing high-quality survivorship care programs within their practice. The...

Daniel F. Hayes, MD, FASCO, Leader in Translational Research, Begins Term as ASCO President

In 1995, Daniel F. Hayes, MD, FASCO, gathered with several other oncologists at a conference center in San Francisco to begin writing the first-ever ASCO guidelines on cancer treatment. He and his colleagues felt like pioneers scouting uncharted frontier. “I’ll never forget, that first hour or so, ...

ASCO and CancerLinQ Participated in Landmark Cancer Moonshot Summit

ASCO Chief Executive Officer Clifford A. Hudis, MD, ­FASCO, and CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick attended Vice President Joe Biden’s Cancer Moonshot Summit at Howard University on Wednesday, June 29, 2016. Along with leaders and stakeholders across the cancer research and...

geriatric oncology
survivorship

The Complexities of Care for Older Cancer Survivors

Integrated care, a focus on prevention and screening, and acknowledgment of comorbidities on the impact of treatment all play a critical role in the cancer survivorship of older patients, according to Martine Extermann, MD, PhD, a medical oncologist at Moffitt Cancer Center in Tampa, Florida....

lymphoma

Identification of Genetic Variants Associated With Extranodal Natural Killer T-Cell Lymphoma

In a genome-wide association study reported in The Lancet Oncology, Li et al identified genetic variants associated with the risk of nasal-type extranodal natural killer T-cell lymphoma (NKTCL). This rare aggressive malignancy is seen predominantly in Asian and Latin American populations;...

breast cancer
issues in oncology

Potential Link Between Obesity and Cardiotoxicity From Anthracyclines Alone or With Trastuzumab for Breast Cancer

Obesity and being overweight were associated with an increased risk of cardiotoxicity in women receiving treatment with anthracyclines and sequential anthracyclines/trastuzumab (Herceptin) for breast cancer, according to a systematic review and meta-analysis reported in the Journal of Clinical...

solid tumors
issues in oncology

Increased Obesity Rates Reported in Adults With a History of Cancer

In a population-based study reported in the Journal of Clinical Oncology, Greenlee et al found that rates of obesity have increased more in patients with a history of cancer than in the general population. These rates were particularly high among survivors of colorectal and breast cancers and black ...

supportive care
symptom management

More Focus Needed on Chemotherapy-Induced Nausea as a Cluster of Symptoms

Management of chemotherapy-induced vomiting has improved with the use of antiemetics, but chemotherapy-induced nausea remains a major clinical problem, according to Alex Molassiotis, RN, PhD, Professor and Head of the School of Nursing at The Hong Kong Polytechnic University. And, he added, the...

supportive care
symptom management
breast cancer

Use of Dexamethasone Mouthwash in Managing mTOR Inhibitor–Associated Stomatitis in Patients With Breast Cancer

Prophylactic use of dexamethasone mouthwash significantly minimized the incidence of all grades of stomatitis in postmenopausal women receiving everolimus (Afinitor, Zortress) and exemestane for the treatment of hormone receptor–positive metastatic breast cancer, according to data presented by...

supportive care
symptom management

Dealing With GI Toxicities After Chemoradiation

Chemotherapy- and radiotherapy-induced gastrointestinal (GI) toxicities have risen alongside improved survival rates for many cancers, according to Jervoise Andreyev, MA, PhD, Consultant Gastroenterologist in GI Consequences of Cancer Treatment at the Royal Marsden Hospital in London. “For every...

colorectal cancer

Anti–Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo in Advanced Colorectal Cancer

A novel anti–interleukin-1 alpha (IL-1α) antibody has shown a significant impact on symptoms and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented by Hickish et al at the European Society for Medical Oncology’s 18th World...

gastrointestinal cancer

Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Postoperative Chemotherapy

Postoperative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared with postoperative chemotherapy in patients with gastric cancer who have already undergone preoperative chemotherapy, according to phase III data presented by Marcel Verheij, MD, PhD, et...

hepatobiliary cancer

Phase III RESORCE Study Data Show Regorafenib Improves Overall Survival in Previously Treated Patients With Unresectable Liver Cancer

Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Jordi Bruix, MD, et al...

colorectal cancer

Anti–PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination With MEK Inhibition

Anti–PD-L1 (programmed death ligand 1) immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the European Society for Medical Oncology (ESMO) 18th World Congress on...

head and neck cancer
issues in oncology

New Study Finds Increase in Imaging After Thyroid Cancer Treatment Identifies Recurrence but May Not Improve Survival

More imaging after thyroid cancer treatment identifies recurrence, but it does not always improve survival, a new study published by Banerjee et al in The BMJ suggests. Researchers from the University of Michigan Comprehensive Cancer Center looked at 28,220 patients diagnosed with...

breast cancer

African American Women More Likely to Choose Autologous Breast Reconstruction Over Implant-Based Reconstruction

African American women undergoing mastectomy for breast cancer are more likely than white women to undergo autologous breast reconstruction using their own tissue, rather than implant-based reconstruction, reported Sharma et al in Plastic and Reconstructive Surgery. “African American race...

lung cancer

AAPM 2016: Somatic Mutations and PET-Based Radiomic Features in Non–Small Cell Lung Cancer

A cutting-edge method of extracting big data from positron-emission tomography (PET) images can provide additional information to quantify lung tumors caused by a genetic mutation. This information could help guide the most effective treatment, suggest findings of a study of nearly 350 patients...

breast cancer

Social Media Engagement May Be Linked to More Satisfaction With Breast Cancer Treatment Decisions

Women who engaged on social media after a breast cancer diagnosis expressed more deliberation about their treatment decision and more satisfaction with the path they chose, a new study from the University of Michigan Comprehensive Cancer Center finds. Findings were published by Wallner et al in...

gynecologic cancers

Recommendations for Surveillance of Premature Ovarian Insufficiency in Female Survivors of CAYA Cancers

Harmonized recommendations for surveillance of premature ovarian insufficiency in female survivors of childhood, adolescent, and young adult (CAYA) cancers have been published by van Dorp et al in the Journal of Clinical Oncology on behalf of the International Late Effects of Childhood Cancer...

hematologic malignancies
lymphoma

High Cumulative Burden of Cardiovascular Morbidity in Young Survivors of Hodgkin Lymphoma

In an analysis from the St. Jude Lifetime Cohort Study reported in The Lancet Oncology, Bhakta et al found a high cumulative burden of cardiovascular morbidity among pediatric, adolescent, and young adult survivors of Hodgkin lymphoma. Study Details The study involved data from 670 survivors of...

breast cancer
solid tumors

Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer

As reported by Rugo et al and Park et al in The New England Journal of Medicine, the adaptive randomization phase II I-SPY 2 trial has shown that the addition of veliparib/carboplatin and the addition of neratinib to standard neoadjuvant therapy have met criteria predictive of success in a phase...

lymphoma

CAR T-Cell Therapy Promising in Non-Hodgkin Lymphoma

Research conducted at the Fred Hutchinson Cancer Research Center, Seattle, is moving the field of chimeric antigen receptor (CAR) T-cell therapy forward in the treatment of B-cell malignancies. At the 2016 Pan Pacific Lymphoma Conference in Koloa, Hawaii, David G. Maloney, MD, PhD, Professor of...

Expert Point of View: W. Robert Lee, MD

Formal discussant W. Robert Lee, MD, of Duke University School of Medicine, Durham, North Carolina, placed himself firmly in the camp supporting hypofractionation as a new standard of care. “We now have three large noninferiority trials with different eligibility criteria and different regimens....

prostate cancer

Hypofractionation May Be Poised to Become New Standard of Care for Prostate Cancer

There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or conventional radiotherapy (given over 8–9 weeks). A new study presented at the 2016 ASCO Annual Meeting...

issues in oncology
health-care policy

Moonshots and ‘Onco-nauts’

Where were you on July 20, 1969? I certainly remember where I was—sitting in a mess hall at summer camp watching a grainy black-and-white TV as Neil Armstrong took “one small step for man, one giant leap for mankind.” I recall the sense of jubilation and accomplishment that all American citizens...

issues in oncology

ASCO and Friends of Cancer Research Launch Initiative to Modernize Eligibility Criteria for Clinical Trials

The dismal accrual rates in cancer clinical trials are well known: Just 3% to 5% of adults with cancer enroll in clinical trials.1 The reasons patients are reluctant to participate in clinical trials are equally well known: fear of reduced quality of life, concern about receiving a placebo, and...

cost of care

ASCO Plenary Studies: Assessing the ‘Value’ of New Treatments

At the 2016 ASCO Annual Meeting, studies presented at the Plenary Session gave attendees new treatment strategies to employ back home. But in the emerging push to contain the cost of new cancer treatments, do the four interventions fit within the new “value framework” for oncology? Deborah Schrag, ...

survivorship
pain management

ASCO Releases Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers

As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers. The guideline was based on literature review by an expert panel, with ...

breast cancer

Insurance, Distance to Care Can Be Barriers to Breast Reconstruction

Women were less likely to have breast reconstruction surgery after mastectomy if they had Medicaid or Medicare rather than private insurance or if they lived 10 or more miles from a plastic surgeon’s office, a University of North Carolina (UNC) Lineberger Comprehensive Cancer Center study has ...

breast cancer

Sampling Method Used for New Breast Cancer Tests May Lead to Underestimation of Risk

Not only is breast cancer more than one disease, but a single breast cancer tumor can vary within itself, a finding that University of Pittsburgh Cancer Institute (UPCI) researchers discovered has the potential to lead to very different patient treatment plans depending on the tumor sample and...

skin cancer

Potential Link Between Pembrolizumab Use and Demyelinating Polyradiculoneuropathy Reported in Two Cases of Advanced Melanoma

In a letter to the editor in The New England Journal of Medicine, de Maleissye et al described two cases of severe demyelinating polyradiculoneuropathy that occurred after pembrolizumab (Keytruda) treatment for advanced melanoma. Case 1 A 45-year-old woman receiving pembrolizumab at 2 mg/kg every ...

gastroesophageal cancer

Association Between Germline Mutation in VSIG10L and Barrett's Esophagus/Esophageal Cancer

Researchers at University Hospitals Case Medical Center have discovered that a rare genetic mutation is associated with susceptibility to familial Barrett's esophagus and esophageal cancer. The findings were published by Fecteau et al in JAMA Oncology. Amitabh Chak, MD, of University Hospitals...

prostate cancer

Sociodemographic and Clinical Predictors of Switching to Active Treatment From Observational Management in Low-Risk Prostate Cancer

Although active surveillance for patients with low-risk prostate cancer has become an increasingly acceptable strategy for disease management, many men opt for definitive therapies such as radical prostatectomy or radiation therapy. A new study of more than 2,200 patients with low-risk prostate...

colorectal cancer

No Improvement in Outcome Reported With Longer Wait Between Radiochemotherapy and Surgery in Rectal Cancer

Pathologic complete response rate was not improved by increasing the interval between neoadjuvant chemoradiotherapy and surgery from 7 to 11 weeks in patients with rectal cancer, according to the French phase III GRECCAR-6 trial reported by Lefevre et al in the Journal of Clinical Oncology. In...

skin cancer

Combining Ipilimumab With Radiotherapy or Electrochemotherapy May Prolong Survival in Patients With Advanced Melanoma

The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. A study by Theurich et al investigating the benefits of combining ipilimumab with local peripheral treatments, such as...

gynecologic cancers

Potential Increased Risk of Serous/Serous-like Endometrial Carcinoma After RRSO in Women With BRCA1 Mutation

In a prospective cohort study reported in JAMA Oncology, Shu et al found that risk for serous/serous-like endometrial carcinoma appeared to be increased after risk-reducing salpingo-oophorectomy (RRSO) without hysterectomy in women harboring the BRCA1 mutation. The overall risk of uterine cancer...

leukemia

Study Evaluates Chronic Graft-vs-Host Disease Burden and Complications in Patients Receiving Bone Marrow Transplants

A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009 to 2014, finding that 3 years post transplant, the incidence of severe chronic graft-vs-host disease was significantly higher in patients who had received transplants from ...

cns cancers

Effect of Radiosurgery Alone vs Radiosurgery Plus WBRT on Cognitive Function in Patients With Brain Metastases

Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study published by Brown et al in JAMA. The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery (SRS) alone, compared...

skin cancer

Pathway Defects in Acquired Resistance to PD-1 Inhibition in Melanoma Identified

In a study reported in The New England Journal of Medicine, Zaretsky et al found that defects in interferon receptor signaling and antigen-presenting pathways were associated with acquired resistance to PD-1 (programmed cell death protein 1) inhibition in melanoma. Resistance Mutations Identified ...

solid tumors
lung cancer

Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy

Crinò et al found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori) and chemotherapy, according to the ASCEND-2 phase II...

Advertisement

Advertisement




Advertisement